2018
Prostate Cancer Genomic Classifier Relates More Strongly to Gleason Grade Group Than Prostate Imaging Reporting and Data System Score in Multiparametric Prostate Magnetic Resonance Imaging-ultrasound Fusion Targeted Biopsies
Martin DT, Ghabili K, Levi A, Humphrey PA, Sprenkle PC. Prostate Cancer Genomic Classifier Relates More Strongly to Gleason Grade Group Than Prostate Imaging Reporting and Data System Score in Multiparametric Prostate Magnetic Resonance Imaging-ultrasound Fusion Targeted Biopsies. Urology 2018, 125: 64-72. PMID: 30552940, DOI: 10.1016/j.urology.2018.12.001.Peer-Reviewed Original ResearchConceptsPI-RADSv2 scoreDecipher scoreProstate Imaging ReportingDecipher testingTargeted biopsiesRadical prostatectomyData System version 2 (PI-RADS v2) scoreFavorable intermediate-risk prostate cancerIntermediate-risk prostate cancer patientsGleason Grade Group 1Imaging ReportingIntermediate-risk prostate cancerMultivariable logistic regression analysisHigh-risk diseasePI-RADS 4Grade group 1Gleason grade groupProstate cancer patientsMultiparametric magnetic resonancePI-RADS scoreVersion 2 scoreData System scoreLogistic regression analysisSignificant differencesPI-RADS categoryGenomic Heterogeneity and the Small Renal Mass
Ueno D, Xie Z, Boeke M, Syed J, Nguyen KA, McGillivray P, Adeniran A, Humphrey P, Dancik GM, Kluger Y, Liu Z, Kluger H, Shuch B. Genomic Heterogeneity and the Small Renal Mass. Clinical Cancer Research 2018, 24: 4137-4144. PMID: 29760223, PMCID: PMC6125159, DOI: 10.1158/1078-0432.ccr-18-0214.Peer-Reviewed Original Research
2017
Negative Multiparametric Magnetic Resonance Imaging of the Prostate Predicts Absence of Clinically Significant Prostate Cancer on 12-Core Template Prostate Biopsy
Lu AJ, Syed JS, Nguyen KA, Nawaf CB, Rosoff J, Spektor M, Levi A, Humphrey PA, Weinreb JC, Schulam PG, Sprenkle PC. Negative Multiparametric Magnetic Resonance Imaging of the Prostate Predicts Absence of Clinically Significant Prostate Cancer on 12-Core Template Prostate Biopsy. Urology 2017, 105: 118-122. PMID: 28322902, DOI: 10.1016/j.urology.2017.01.048.Peer-Reviewed Original ResearchConceptsMultiparametric magnetic resonance imagingSignificant prostate cancerProstate cancerNegative predictive valueMagnetic resonance imagingSystematic TRUSNegative mpMRIProstate biopsyNegative multiparametric magnetic resonance imagingPredictive valueResonance imagingClinically Significant Prostate CancerDynamic contrast enhancement sequencesTemplate mapping biopsyPrior negative biopsySystematic prostate biopsyOverall cancer detectionProstate-specific antigenTemplate prostate biopsyProstate cancer detectionDiffusion-weighted imagingCancer detectionBiopsy naïveMapping biopsyProstate volume
2016
Konsenskonferenz 2014 der ISUP zur Gleason-Graduierung des Prostatakarzinoms
Kristiansen G, Egevad L, Amin M, Delahunt B, Srigley J, Humphrey P, Epstein J, Graduierungskommittee. Konsenskonferenz 2014 der ISUP zur Gleason-Graduierung des Prostatakarzinoms. Die Pathologie 2016, 37: 17-26. PMID: 26809207, DOI: 10.1007/s00292-015-0136-6.Peer-Reviewed Original Research
2015
NFATc1 promotes prostate tumorigenesis and overcomes PTEN loss-induced senescence
Manda K, Tripathi P, Hsi A, Ning J, Ruzinova M, Liapis H, Bailey M, Zhang H, Maher C, Humphrey P, Andriole G, Ding L, You Z, Chen F. NFATc1 promotes prostate tumorigenesis and overcomes PTEN loss-induced senescence. Oncogene 2015, 35: 3282-3292. PMID: 26477312, PMCID: PMC5012433, DOI: 10.1038/onc.2015.389.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBlotting, WesternCell LineCell Line, TumorCell ProliferationCell Transformation, NeoplasticCellular SenescenceCytokinesGene Expression Regulation, NeoplasticHumansImmunohistochemistryMaleMice, KnockoutMice, NudeMice, TransgenicNFATC Transcription FactorsProstateProstatic NeoplasmsPTEN PhosphohydrolaseReverse Transcriptase Polymerase Chain ReactionTransplantation, HomologousTumor Cells, CulturedTumor MicroenvironmentConceptsProstate tumorigenesisHuman PCaNFATc1 activationNon-tumorigenic prostate cellsActivated T cells c1Cultured PCa cellsT cells c1Cellular senescenceRole of NFATc1Number of cytokinesActivation of NFATc1Proinflammatory cytokinesPCa cellsProstate cancerProstatic adenocarcinomaLuminal epitheliumMouse prostateCells c1Normal prostateOncogenic roleOncogene c-mycProstate tissueProstate cellsSoluble factorsNuclear factor
2009
Loss of Nkx3.1 leads to the activation of discrete downstream target genes during prostate tumorigenesis
Song H, Zhang B, Watson M, Humphrey P, Lim H, Milbrandt J. Loss of Nkx3.1 leads to the activation of discrete downstream target genes during prostate tumorigenesis. Oncogene 2009, 28: 3307-3319. PMID: 19597465, PMCID: PMC2746257, DOI: 10.1038/onc.2009.181.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAtrophyClusterinDisease Models, AnimalDisease ProgressionDown-RegulationGene DeletionGene Expression ProfilingGene Expression Regulation, NeoplasticHomeodomain ProteinsHumansLasersMaleMiceMicrodissectionOxidoreductases Acting on Sulfur Group DonorsProstateProstatic NeoplasmsProto-Oncogene Proteins c-aktProto-Oncogene Proteins c-mycPTEN PhosphohydrolaseSignal TransductionThioredoxinsTranscription FactorsTranscription, GeneticTranscriptional ActivationConceptsNKX3.1 lossMolecular consequencesGene expressionProstate tumorigenesisPTEN-AKTCancer initiationProstate cancer initiationCohort of genesNumber of genesC-Myc signaling pathwayDownstream target genesHuman prostate tumorigenesisLoss of NKX3.1NKX3.1 expressionTumor suppressor geneGene expression data setsExpression data setsQuiescin Q6Transcriptional regulatorsIndependent lossesExpression of NKX3.1Laser capture microdissectionTarget genesCancer gene expression data setsSignaling pathways
2008
Prognostic value of various morphometric measurements of tumour extent in prostate needle core tissue
Brimo F, Vollmer R, Corcos J, Kotar K, Bégin L, Humphrey P, Bismar T. Prognostic value of various morphometric measurements of tumour extent in prostate needle core tissue. Histopathology 2008, 53: 177-183. PMID: 18752501, DOI: 10.1111/j.1365-2559.2008.03087.x.Peer-Reviewed Original ResearchConceptsPathological stageTumor lengthPrognostic valueTumor extentFinal pathological stageHigher stage diseaseNeedle biopsy specimenCancer patient outcomesPrognostic significanceBiochemical recurrenceBiopsy specimenRadical prostatectomyPatient outcomesBiopsy reportingFailure statusCancer lengthPositive coresPathological outcomesLarger studyMorphometric measurementsDiscontinuous fociCancerCore tissuePatientsOutcomes
2006
Genomic aberrations are rare in urothelial neoplasms of patients 19 years or younger
Wild P, Giedl J, Stoehr R, Junker K, Boehm S, van Oers J, Zwarthoff E, Blaszyk H, Fine S, Humphrey P, Dehner L, Amin M, Epstein J, Hartmann A. Genomic aberrations are rare in urothelial neoplasms of patients 19 years or younger. The Journal Of Pathology 2006, 211: 18-25. PMID: 17072825, DOI: 10.1002/path.2075.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAlphapapillomavirusChildChild, PreschoolChromosome AberrationsChromosomes, Human, Pair 9DNA Mismatch RepairDNA Mutational AnalysisDNA, ViralFemaleGene Expression ProfilingGenes, p53HumansImmunohistochemistryIn Situ Hybridization, FluorescenceLoss of HeterozygosityMaleMicrosatellite InstabilityOligonucleotide Array Sequence AnalysisPapillomaPolymerase Chain ReactionReceptor, Fibroblast Growth Factor, Type 3Urologic NeoplasmsUrotheliumConceptsPatients 19 yearsUrothelial neoplasmsUrothelial papillomaMicrosatellite instabilityClinical outcomesHuman papillomavirusTP53 mutationsHigh-grade papillary urothelial carcinomaNIH consensus panelEvidence of diseaseFavorable clinical outcomeLow malignant potentialChromosome arm 9pPapillary urothelial carcinomaComparative genomic hybridizationPapillary urothelial neoplasmHPV positivityYounger patientsMultifocal tumorsUrothelial carcinomaUrothelial tumorsMalignant potentialPolymerase chain reactionConsensus panelKi-67
2004
EFFECT OF THE DUAL 5α-REDUCTASE INHIBITOR DUTASTERIDE ON MARKERS OF TUMOR REGRESSION IN PROSTATE CANCER
ANDRIOLE G, HUMPHREY P, RAY P, GLEAVE M, TRACHTENBERG J, THOMAS L, LAZIER C, RITTMASTER R. EFFECT OF THE DUAL 5α-REDUCTASE INHIBITOR DUTASTERIDE ON MARKERS OF TUMOR REGRESSION IN PROSTATE CANCER. Journal Of Urology 2004, 172: 915-919. PMID: 15310997, DOI: 10.1097/01.ju.0000136430.37245.b9.Peer-Reviewed Original ResearchConceptsProstate cancerMicrovessel densityDutasteride treatmentIntraprostatic dihydrotestosteroneTumor regressionDual 5α-Reductase Inhibitor DutasterideShort-term pilot studyDays of placeboEffect of dutasterideIntraprostatic androgen levelsT2 prostate cancerDegree of atrophyProstate cancer treatmentShort-term treatmentProstate cancer tissuesIndex of apoptosisRadical prostatectomyEarly treatmentAndrogen levelsDutasterideCancer tissuesResected tissuesDHT formationDihydrotestosteroneType 1
2003
Renal sinus haemangioma with inferior vena cava involvement
BHAYANI S, HUMPHREY P, KIBEL A. Renal sinus haemangioma with inferior vena cava involvement. BJU International 2003, 92: e53-e53. PMID: 19127684, DOI: 10.1111/j.1464-410x.2003.04195.x.Peer-Reviewed Original Research
2001
The Relative Importance of Anatomic and PSA Factors to Outcomes After Radical Prostatectomy for Prostate Cancer
Vollmer R, Humphrey P. The Relative Importance of Anatomic and PSA Factors to Outcomes After Radical Prostatectomy for Prostate Cancer. American Journal Of Clinical Pathology 2001, 116: 864-870. PMID: 11764075, DOI: 10.1309/7mq7-mwar-4w8a-r75f.Peer-Reviewed Original ResearchConceptsElevated PSA levelsEarly deathPSA levelsRadical prostatectomyProstate cancerPathology observationsGleason grade 5Overall good prognosisTime of prostatectomyPostoperative levelsPSA failureStudy patientsBetter prognosisProgressive tumorsPrognostic categoriesPercentage carcinomaProstatectomySubsequent outcomesLower hazardDeathSurgeryHigher hazardCancerMenPSAChromosome 22q dosage in composite extrarenal rhabdoid tumors: Clonal evolution or a phenotypic mimic?
Fuller C, Pfeifer J, Humphrey P, Bruch L, Dehner L, Perry A. Chromosome 22q dosage in composite extrarenal rhabdoid tumors: Clonal evolution or a phenotypic mimic? Human Pathology 2001, 32: 1102-1108. PMID: 11679945, DOI: 10.1053/hupa.2001.28252.Peer-Reviewed Original ResearchVisceral primitive peripheral neuroectodermal tumors: A clinicopathologic and molecular study
O'Sullivan M, Perlman E, Furman J, Humphrey P, Dehner L, Pfeifer J. Visceral primitive peripheral neuroectodermal tumors: A clinicopathologic and molecular study. Human Pathology 2001, 32: 1109-1115. PMID: 11679946, DOI: 10.1053/hupa.2001.28247.Peer-Reviewed Original ResearchMeSH KeywordsAbdominal NeoplasmsAdolescentAdultBiomarkers, TumorDNA PrimersDNA, NeoplasmFemaleHumansImmunoenzyme TechniquesMaleMiddle AgedNeoplasm ProteinsNeuroectodermal Tumors, Primitive, PeripheralOncogene Proteins, FusionProto-Oncogene Protein c-fli-1Reverse Transcriptase Polymerase Chain ReactionRNA, MessengerRNA, NeoplasmRNA-Binding Protein EWSSarcoma, EwingSoft Tissue NeoplasmsTomography, X-Ray ComputedTranscription FactorsVisceraConceptsEWS/PNETSoft tissuePediatric small round blue cell tumorsSarcoma-primitive neuroectodermal tumorPolymerase chain reaction-based testingFusion transcriptsSmall round blue cell tumorsRound blue cell tumorsBlue cell tumorsClinicopathologic spectrumVisceral sitesPrognostic significanceVisceral originVisceral tumorsCell tumorsNeuroectodermal tumorAdditional casesTumorsPNETYoung adultsGenetic alterationsEts transcription factor familyBoneChromosomal translocationsEWS-FLI1Frequent and early loss of the EGR1 corepressor NAB2 in human prostate carcinoma
Abdulkadir S, Carbone J, Naughton C, Humphrey P, Catalona W, Milbrandt J. Frequent and early loss of the EGR1 corepressor NAB2 in human prostate carcinoma. Human Pathology 2001, 32: 935-939. PMID: 11567222, DOI: 10.1053/hupa.2001.27102.Peer-Reviewed Original ResearchConceptsHuman prostate cancerHuman prostate carcinomaProstate cancerProstate carcinomaProstatic intraepithelial neoplasia lesionsIntraepithelial neoplasia lesionsProstate carcinoma specimensExpression of Nab2Prostate tumor suppressorNeoplasia lesionsTumor gradeCarcinoma specimensProstate tumorigenesisTumor progressionTranscription factor EGR1Protein expressionEarly lossEGR1 levelsCarcinomaTumorigenic processCancerTumor suppressorSame stimuliEGR1Transcriptional activityLatent Prostate Carcinoma in a Screened Population
Kibel A, Humphrey P. Latent Prostate Carcinoma in a Screened Population. European Urology 2001, 39: 35-36. PMID: 11340287, DOI: 10.1159/000052583.Peer-Reviewed Original ResearchSCATTER FACTOR-HEPATOCYTE GROWTH FACTOR ELEVATION IN THE SERUM OF PATIENTS WITH PROSTATE CANCER
NAUGHTON M, PICUS J, ZHU X, CATALONA W, VOLLMER R, HUMPHREY P. SCATTER FACTOR-HEPATOCYTE GROWTH FACTOR ELEVATION IN THE SERUM OF PATIENTS WITH PROSTATE CANCER. Journal Of Urology 2001, 165: 1325-1328. PMID: 11257710, DOI: 10.1016/s0022-5347(01)69893-8.Peer-Reviewed Original ResearchConceptsMetastatic prostate cancerProstate cancerMetastatic diseaseHepatocyte growth factorPatient ageSerum levelsNegative sextant prostate biopsiesProstate-specific antigen levelHuman prostate cancer cell linesAvailable enzyme-linked immunosorbentSextant prostate biopsySpecific antigen levelsNegative sextant biopsiesProstate cancer cell linesSera of patientsImportant serum markerLogistic regression analysisEnzyme-linked immunosorbentCancer cell linesLocalized cancerRadiographic evidenceSerum markersAntigen levelsSextant biopsyProstate biopsyPrimitive Neuroectodermal Tumors of the Biliary and Gastrointestinal Tracts: Clinicopathologic and Molecular Diagnostic Study of Two Cases
Sarangarajan R, Hill D, Humphrey P, Hitchcock M, Dehner L, Pfeifer J. Primitive Neuroectodermal Tumors of the Biliary and Gastrointestinal Tracts: Clinicopathologic and Molecular Diagnostic Study of Two Cases. Pediatric And Developmental Pathology 2001, 4: 185-191. PMID: 11178636, DOI: 10.1007/s100240010141.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentBile Duct NeoplasmsBiomarkers, TumorDNA PrimersDNA, NeoplasmFemaleHepatic Duct, CommonHumansImmunoenzyme TechniquesJejunal NeoplasmsMaleNeoplasm ProteinsNeoplasms, Second PrimaryNeuroectodermal Tumors, Primitive, PeripheralReverse Transcriptase Polymerase Chain ReactionRNA, NeoplasmSequence Analysis, DNAWilms TumorConceptsPrimitive neuroectodermal tumorNeuroectodermal tumorMalignant small round cell tumorMalignant soft tissue tumorsSmall round cell tumorSoft tissue tumorsRound cell tumorNon-classical sitesMore conventional sitesEWS-FLI1 gene fusionMolecular diagnostic studiesTranscription-polymerase chain reaction analysisCharacteristic immunoreactivityHepatic ductCell tumorsClinicopathologic profileTissue tumorsGastrointestinal tractChain reaction analysisUnusual siteSmall intestineTumorsMolecular findingsTumor cellsDiagnostic studiesImpaired prostate tumorigenesis in Egr1-deficient mice
Abdulkadir S, Qu Z, Garabedian E, Song S, Peters T, Svaren J, Carbone J, Naughton C, Catalona W, Ackerman J, Gordon J, Humphrey P, Milbrandt J. Impaired prostate tumorigenesis in Egr1-deficient mice. Nature Medicine 2001, 7: 101-107. PMID: 11135623, DOI: 10.1038/83231.Peer-Reviewed Original ResearchConceptsEarly growth response protein 1Prostate cancerTumor progressionProstatic intra-epithelial neoplasiaEgr1 deficiencyIntra-epithelial neoplasiaHigh-resolution magnetic resonance imagingTransgenic mouse modelHuman prostate cancerTumor growth rateEgr1-deficient miceMagnetic resonance imagingProstate tumor progressionMouse modelProstate tumorigenesisSurvival analysisResonance imagingCarcinomaTumor developmentProtein 1ProgressionCancerMiceDeficiencyEGR1Interobserver reproducibility of Gleason grading of prostatic carcinoma: Urologic pathologists
Allsbrook W, Mangold K, Johnson M, Lane R, Lane C, Amin M, Bostwick D, Humphrey P, Jones E, Reuter V, Sakr W, Sesterhenn I, Troncoso P, Wheeler T, Epstein J. Interobserver reproducibility of Gleason grading of prostatic carcinoma: Urologic pathologists. Human Pathology 2001, 32: 74-80. PMID: 11172298, DOI: 10.1053/hupa.2001.21134.Peer-Reviewed Original ResearchConceptsUrologic pathologistsProstatic carcinomaInterobserver reproducibilityGleason scoreGleason gradingGleason grade groupLow-grade tumorsCribriform proliferationNeedle biopsyGroup 2Gleason patternGrading systemCarcinomaGrade groupTumorsPathologistsScoresGradingKappa coefficientBiopsyHistologyCoefficient kappa
2000
Overexpression and regulation of expression of scatter factor/hepatocyte growth factor in prostatic carcinoma
Zhu X, Humphrey P. Overexpression and regulation of expression of scatter factor/hepatocyte growth factor in prostatic carcinoma. Urology 2000, 56: 1071-1074. PMID: 11113771, DOI: 10.1016/s0090-4295(00)00795-0.Peer-Reviewed Original ResearchConceptsPlatelet-derived growth factorVascular endothelial growth factorHGF expressionSF/HGF expressionEndothelial growth factorGrowth factorProstatic carcinomaIL-1betaStromal myofibroblastsProstatic tissueSF/HGFCarcinoma tissuesGrowth factors basic fibroblast growth factorCell linesProstatic epithelial cell linesHuman prostatic carcinoma tissueHuman prostatic tissue samplesProstatic tissue samplesProstatic carcinoma tissueBenign prostatic tissueHuman prostatic carcinomaHuman prostatic tissueMalignant human prostatic tissuesMultifunctional polypeptide growth factorsEnzyme-linked immunosorbent